You are here

Attenuated Shigella as Vector for Helicobacter Vaccine

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 AI38124-01,
Agency Tracking Number: 29119
Amount: $86,331.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1995
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
230 Albany Street
Cambridge, MA 02139
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 William Thomas
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract

Our goal is to develop a live vector vaccine against Helicobacter pylori by expression of urease inShigella flexneri 2A strains and testing the ability of these strains to induce a protective mucosalmice. Helicobacter pylori ureases will be expressed in attenuated S. flexneri strains to assess theoral vaccine vector. OraVax and others have demonstrated that oral immunization with H. pylori ureasprotective response against H. felis infection in mice when administered along with Cholera Toxin asAttenuated S. flexneri 2A (CVD1203) expressing urease will be constructed and used to immunize mice.immunity to Helicobacter infection will be assessed by subsequent challenge with H. felis. These expthe use of a live vector approach to immunization against H. pylori as an alternative to toxic mucosof these preliminary experiments will provide the basis for Phase II experiments using non-human priShigella and H. pylori to confirm the efficacy of live attenuated S. flexneri 2A strains as vaccine

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government